Currently, upfront programmed death ligand 1 (PD-L1) expression testing before first-line therapy is also a recommendation (regardless of the histology) for patients with advanced or metastatic NSCLC, in order to assess how immune checkpoint inhibitors could be used if no actionable molecular biomarkers are identified [44,45]. Here, CD274 is linked to non-small cell lung carcinoma.